Drug-drug interactions of anti-infective drugs: Utility of fluorescence CYP inhibition assays in drug discovery

Drug Metabolism and Drug Interactions

Volumn 21, Issue 3-4, 2006, Pages 163-185

  Fridén, Markus ^a   Vanaja, K ^b   Nandi, Vrinda N ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Anti infective drugs; Clinical significance; CYP inhibition; Drug drug interactions

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; ANTIINFECTIVE AGENT; CEFACLOR; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CLOTRIMAZOLE; COMPLEMENTARY DNA; CYTOCHROME P450; ENZYME INHIBITOR; ETHAMBUTOL; ISOENZYME; ISONIAZID; METRONIDAZOLE; PIPERACILLIN; PYRAZINAMIDE; ROXITHROMYCIN; SALAZOSULFAPYRIDINE; STREPTOMYCIN; SULFAPHENAZOLE; TOBRAMYCIN; TRIMETHOPRIM; TROLEANDOMYCIN; VANCOMYCIN; ZIDOVUDINE;

ARTICLE; CORRELATION FUNCTION; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; ENZYME INHIBITION; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; GENE EXPRESSION; HYDROXYLATION; IC 50; ISOENZYME ANALYSIS; LIVER MICROSOME; NONHUMAN;

EID: 33745652497     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2006.21.3-4.163     Document Type: Article

References (51)

1. Fee JPH, Collier PS, Howard PJ, Dundee JW. Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 1987; 41: 80-84.
2. Woosely RL, Chen Y, Freiman JP, Gillis RA. Mechanism of cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-1536.
3. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
4. Riley J, Wilton LV, Shakir SAW. A post-marketing observational study to assess the safety of mibefradil in the community in England. Int J Clin Pharmacol Ther 2002; 40: 241-248.
5. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-543.
6. Rodrigues AD, Lin JH. Screening of drug candidates for their drug-drug interaction potential. Curr Opin Chem Biol 2001; 5: 396-401.
7. Shearer TW, Smith KS, Diaz D, Asher C, Ramirez J. The role of in vitro ADME assays in antimalarial drug discovery and development. Comb Chem High Throughput Screening 2005; 8: 89-98.
8. Clarke SE, Jones BC. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. Drugs Pharm Sci 2002; 116: 55-88.
9. Marroum PJ, Spahn-Langguth H, Langguth P. Scientific, mechanistic and regulatory issues with pharmacokinetics drug-drug interactions. Drugs Pharm Sci 2004; 141 (New Drug Development): 297-343.
10. U.S. Food and Drug Administration. Guidance for Industry Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro. 1997. http://www.fda.gov/cber/cberftp.html.
11. Den Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother 1998; 42: 744-748.
12. Tumridge J. Pharmacokinetics and pharmacodynamics of fluroquinolone. Drugs 1999; 58 (Suppl 2): 29-36.
13. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32: S39-S46.
14. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 2000; 3: 515-521.
15. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33: S233-S237.
16. Slavik RS, Jewesson PJ. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 2003; 42: 793-817.
17. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003; 9: 891-902.
18. Riley RJ. The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Dis Dev 2001; 4: 45-54.
19. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA expressed cytochrome P450s and native liver microsomes. Biochem Pharmacol 1999; 57: 465-480.
20. Crespi CL, Stresser DM. Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Meth 2000; 44: 325-331.
21. Testino SA, Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003; 30: 1459-1467.
22. Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 1999; 29: 53-75.
23. Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolising cytochromes P450. Anal Biochem 1997; 248: 188-190.
24. Favreau LV, Palamanda JR, Lin CC, Nomeir AA. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. Drug Metab Dispos 1999; 27: 436-439.
25. Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001; 29: 748-753.
26. Lin JH. Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 2000; 1: 305-331.
27. GENTEST Corporation. Technical Bulletin: A High Throughput Method for Measuring Cytochrome P450 Inhibition, Version 4.2, 2000. http://www.gentest.com.
28. Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 1984; 101: 377-386.
29. Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989; 45: 234-240.
30. Schwartz J, Jauregui L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother 1988; 32: 75-77.
31. Waite NM, Rutledge DR, Warbasse LH, Edwards DJ. Disposition of the (+) and (-)-isomers of metoprolol following ciprofloxacin treatment. Pharmacotherapy 1990; 10: 236.
32. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharm Rev 1998; 50: 387-411.
33. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976; 295: 354-357.
34. Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 1988; 28: 240-245.
35. Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K. Interaction of tolbutamide and chloramphenicol in diabetic patients. Int J Clin Phamacol Biopharm 1977; 15: 7-12.
36. Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Colburn WA, Bruck E. Interaction of chloramphenicol with phenytoin and phenobarbital. Clin Pharmacol Ther 1978; 24: 571-575.
37. Markowitz JS, Gill HS, DeVane CL, Mintzer J. Fluoroquinolone inhibition of clozapine metabolism. Am J Psychiatry 1997; 154: 881.
38. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991; 52: 1086-1087.
39. Block SH. Carbamazepine-isoniazid interaction. Pediatrics 1982; 69: 494-495.
40. Miller RR, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. Chest 1979; 75: 356-358.
41. Walubo A, Aboo A. Phenytoin toxicity due to concomitant anti-tuberculosis therapy. S Afr Med J 1995; 85: 1175-1176.
42. Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol 1983; 16: 743-746.
43. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arroe M, Abildgaard U, Skovsted L. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl 1979; 624: 106-110.
44. Christensen LK, Hansen JM, Kristensen M. Sulfophenazole induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 1963; 41: 1298-1301.
45. Pond SM, Birkett DJ, Wade DN. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther 1977; 22: 573-579.
46. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions Anesthesiology 1997; 87: 36-50.
47. Mesdjian E, Dravet C, Cenraud B, Roger J. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 1980; 21: 489-496.
48. Wang JS, Wang W, Xie HG, Huang SL, Zhou HH. Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Br J Clin Pharmacol 1997; 44: 195-198.
49. Weinberger M, Hudgel D, Spector S, Chidsey C. Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 1977; 59: 228-231.
50. Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P, Puech AJ. Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987; 32: 389-393.
51. Backman JT, Aranko K, Himberg J-J, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 1994; 46: 551-555.